Guardant Health (GH) Stock Looks Cheap With Screening Growth In View

Guardant Health has seen its shares climb sharply in recent years, which puts a spotlight on whether the business's cash flows can keep pace with the expectations now baked into the price. With the stock recently closing at US$178.80, the key issue is how that market value lines up against what the company is likely to generate in hard cash over time.

• Over the past 3 years the share price has risen by a very large amount, which places extra weight on whether the current valuation is properly grounded in the cash the business can ultimately produce.
• The push to expand access to colorectal cancer screening through measures like Pennsylvania's House Bill 1123 and the focus on liquid biopsy research and platforms such as InfinityAI can support expectations for future revenue streams and shape the timing and scale of potential cash inflows.
• Prefer to judge Guardant Health on sales? See why Guardant Health's 20.3x P/S tells a different valuation story.

The issue now is whether those cash flow expectations, as captured in a Discounted Cash Flow (DCF) intrinsic value estimate, are enough to justify where Guardant Health shares trade today.

If you want a broader watchlist while you assess Guardant Health's cash flow story, a focused stock screen built around 33 healthcare AI stocks can be a useful additional starting point for research.

Is Guardant Health Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here looks at what Guardant Health might deliver to shareholders in future cash terms. Latest twelve month free cash flow sits at a loss of $232.9 million, so the whole story hinges on a move from cash burn to positive cash generation over the next decade.

Analysts contributing to this DCF framework assume recovering and then growing free cash flow, with projections turning positive and scaling into the hundreds of millions of dollars by the early 2030s. Because the Pennsylvania colorectal cancer screening law directly supports access to Guardant Health's Shield test, that policy tailwind helps explain why the DCF points to an intrinsic value meaningfully above the current share price of US$178.80. Find out what Guardant Health could be worth using our Discounted Cash Flow (DCF) estimate.

The Guardant Health Narrative: What Would Justify Today's Price?

Guardant Health's valuation puzzle points directly to the assumptions behind it, and Simply Wall St Narratives on the Community page explain what would need to be true on future growth, margins and earnings for the stock to be worth materially more or less than it is today. Each narrative links a specific fair value to a clear storyline about Guardant Health's potential catalysts and key risks, so you can track which version of events is taking shape over time.

Community views on Guardant Health split between those who see screening momentum supporting more upside and those who focus on royalties and spending drag.

Bull case: 12% undervalued

"Accelerating adoption of Guardant Health’s blood based colorectal cancer screening Shield, supported by coverage for roughly 70 to 80% of eligible U.S. adults and sharply higher test volumes…"

Discover why this Narrative puts Guardant Health at 12% undervalued.

Bear case: 16% overvalued

"Bearish analysts expect Guardant Health to see its growth case increasingly constrained by the US$245.2 million patent judgment and 6% royalty on most current and historical oncology revenues…"

Explore why this Narrative puts Guardant Health at 16% overvalued.

Guardant Health has one more check investors should weigh

Guardant Health’s story on cash flows and community narratives is only part of the picture, because internal checks have also raised specific concerns that deserve a closer look before any conclusion. Take a closer look at 2 warning signs (1 major) before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com